Navigation Links
Cardinal Health Taps Teva Executive George Barrett to Lead Healthcare Supply Chain Services Sector
Date:1/10/2008

Barrett, David Schlotterbeck Named Vice Chairmen

DUBLIN, Ohio, Jan. 10 /PRNewswire-FirstCall/ -- Cardinal Health, a global provider of products and services that improve the safety and productivity of health care, today announced that George S. Barrett, chief executive officer (CEO) of Teva North America, will join the company as vice chairman of Cardinal Health and CEO of its Healthcare Supply Chain Services sector.

Barrett, 52, will join the company at the end of January and report to Chairman and CEO R. Kerry Clark. He served as corporate executive vice president of Teva's Global Pharmaceutical Markets since January 2007, as well as CEO of Teva North America since January 2005. He was president and CEO of Teva USA from 1999 to 2004.

David L. Schlotterbeck, 60, has also been named vice chairman in addition to his role as CEO of the company's Clinical and Medical Products sector. This sector includes the company's market-leading intravenous infusion, automated dispensing and respiratory systems, and infection prevention products.

"I am very pleased to welcome George to Cardinal Health," Clark said. "His strategic leadership, deep operational experience and outstanding global knowledge of the pharmaceutical industry will help us on our path to becoming the premier global health care company. I am also very grateful to our CFO Jeff Henderson for his strong, interim leadership of the supply chain business during the past three months."

Barrett will be responsible for all of Cardinal Health's supply chain businesses, which comprise the nation's largest distributor of pharmaceuticals and medical supplies to retail and independent pharmacies, hospitals, laboratories and physician offices. This sector operates more than 70 distribution centers, 160 nuclear pharmacies and six surgical kitting facilities. In its most recent fiscal year, the supply chain sector contributed 70 percent of Cardinal Health's consolidated profit
'/>"/>

SOURCE Cardinal Health, Inc.
Copyright©2008 PR Newswire.
All rights reserved

0

GOOD

Page: 1 2 3

Related medicine news :

1. Cardinal Health to Announce Second-Quarter Results on January 29
2. Cardinal Health to Cease Distribution of Controlled Substances from Florida Facility
3. Cardinal Health Foundation Grants $537,000 to Rural, Public Hospitals in Support of IHIS 5 Million Lives Campaign
4. Cardinal Health Receives DEA Order to Temporarily Cease Distribution of Controlled Substances from Auburn, Wash. Facility
5. Cardinal Health, Sentry Data Systems Introduce New Technology to Help Health Care Providers More Cost-Efficiently Care for Underserved
6. Cardinal Health Reports First Quarter Results
7. Cardinal Health Announces Sector Management Change
8. Cardinal Health To Announce First-Quarter Results on November 5
9. Cardinal Health Names CEO R. Kerry Clark as Chairman; Company Founder Robert D. Walter to Retire After 36 Years
10. Cardinal Health Reaffirms Fiscal 2008 EPS Guidance, Updates Segment Profit Outlook
11. Advanced Home Care Extends Its Use of Authentidates Inscrybe(TM) Healthcare Platform

Post Your Comments:
*Name:
*Comment:
*Email:
(Date:11/27/2009)...UILLY-SUR-SEINE,France,Nov.27/PRNewswire/--TeamGar...teamdedicatedtoethicalsportinganddevelopingthenext...illbecomeTeamGarmin-TransitionswiththeadditionofTr...Opticalistheworld,sleadingmanufacturerofadaptiveey...yinthewidestselectionofspectaclelensessuchasTransi...
(Date:11/27/2009)... XenaCare Holdings has announced th...is Foundation, one of the largest nonprofit organi... health education. , Delr... Holdings, Inc. (OTCBB: XCHO), a company specializ...nsumer healthcare products, has announced today th...
(Date:11/27/2009)...tes to bring unprecedented medical, economic burde...HealthDay News) -- The number of people with diabe...r the next 25 years, a new study predicts. , Th...lion people with the disease, up from 23.7 million...ng people with diabetes will triple, the study als...
(Date:11/27/2009)... Voyant Health™ announced tod...as licensed its TraumaCad Enterprise orthopedic te...w solution. , (PRWEB) Nov...oday that Spectrum Health (Grand Rapids, Michigan)...templating solution and its TraumaCad Extend workf...
(Date:11/27/2009)... Specialist manufacturers who use m...re saving millions of dollars by bringing in techn... Increasing numbers of pro-active medical manufact...the concept stage of their projects, ensuring that...gn processes or potentially outdated technology. ...
Breaking Medicine News(10 mins):Health News:Team Garmin-Slipstream Officially Re-named Team Garmin-Transitions With Addition of Transitions Optical as New Sponsor 2Health News:Team Garmin-Slipstream Officially Re-named Team Garmin-Transitions With Addition of Transitions Optical as New Sponsor 3Health News:XenaCare Holdings Announces National Sponsorship of the Arthritis Foundation 2Health News:XenaCare Holdings Announces National Sponsorship of the Arthritis Foundation 3Health News:XenaCare Holdings Announces National Sponsorship of the Arthritis Foundation 4Health News:Diabetes Cases Expected to Double in 25 Years 2Health News:Diabetes Cases Expected to Double in 25 Years 3Health News:Voyant Health Announces: Spectrum Health Licenses TraumaCad Enterprise and TraumaCad Extend 2Health News:Voyant Health Announces: Spectrum Health Licenses TraumaCad Enterprise and TraumaCad Extend 3Health News:Pro-active Manufacturers Save Millions with Advanced Flintec Medical Load Cells 2Health News:Pro-active Manufacturers Save Millions with Advanced Flintec Medical Load Cells 3Health News:Pro-active Manufacturers Save Millions with Advanced Flintec Medical Load Cells 4
...nsula Medical School in the South West of England ...eel that doctors providing out of hours services i... Researchers held group discussions and carried ou...ngland. , Under the GP contract, which came into ...
... 29 CalbaTech, Inc.,(OTC Bulletin Board: CLBE), a...aTech.com ) concentrating on the collection and ba...apeutic uses and providing,products and platforms ...th has renewed LifeStem,s biologics license.,LifeS...
...Role as Governments and Civil Society in the ...Crisis, NEW DELHI, India, BEIJING and BANGKOK, Th...IDS Day 2007, hundreds, perhaps thousands, of men,...but ever-growing crisis that many governments in t...
...the hip is a growing problem that will continue to... have reported on risk factors for developing OA, ...ct its prognosis. A new study published in the Dec...r disease progression and to find out how many und...
...it has obtained agreement with the United States, ...n of its pivotal study, protocol for SP1049C for t... upper gastrointestinal tract, ...rsus BSC alone for the treatment of patients with ...
...) -- There are estimated to be between 50,000 --...ronic Immune Thrombocytopenic Purpura (ITP), an au...ber of platelets in their blood -- causing bruises...rk-Presbyterian Hospital/Weill Cornell Medical Cen...
Other Medicine News:Health News:Out of hours doctors reluctant to do home visits, say patients 2Health News:CalbaTech Reports That LifeStem's Biologics License Has Been Renewed 2Health News:CalbaTech Reports That LifeStem's Biologics License Has Been Renewed 3Health News:New Asia Pacific Statistics Reveal an Alarming Incidence of HIV in MSM 2Health News:New Asia Pacific Statistics Reveal an Alarming Incidence of HIV in MSM 3Health News:New Asia Pacific Statistics Reveal an Alarming Incidence of HIV in MSM 4Health News:New Asia Pacific Statistics Reveal an Alarming Incidence of HIV in MSM 5Health News:New Asia Pacific Statistics Reveal an Alarming Incidence of HIV in MSM 6Health News:Identifying patients at high risk for total hip replacement 2Health News:Supratek Pharma Inc. announced today that under the Special Protocol 2Health News:Eltrombopag studied in Idiopathic Thrombocytopenic Purpura 2
(Date:11/25/2009)...wire-FirstCall/--NuVasive,Inc.(Nasdaq: NUVA ),amed...imallydisruptivesurgicaltreatmentsforthespine,anno...vember30,2009,at5:30p.m.ET/2:30p.m.PT.Theconferenc...ntfortheCompany,sproductsandwillincludecommentsfro...n.Thedial-innumbersare1-877-407-4018fordomesticcal...
(Date:11/25/2009)...dJOHANNESBURG,November25/PRNewswire/--,iThembaPhar...cedtoday,thattheyhavesignedacollaborativeagreement...is,sworldclasscomputationalchemistryandleaddiscove...iontoprovidemedicinaland,syntheticchemistrysupport...entnetwork.iThembaPharmaceuticalsandPyxisDiscovery...
(Date:11/24/2009)...wswire/-- ,, WHAT:RomHoubens,aBelgianmanthought...wasactuallyfullyconsciousandawakeduringthattimeand...oxEyeMaxwasfeaturedinthesegmenttoillustratehowpeop...communication. ,, WHEN:GoodMorningAmerica-- Tue...ch.com ,, WHO:RomHoubenswasanengineeringstu...
Breaking Medicine Technology:NuVasive Announces Conference Call and Webcast Regarding Reimbursement 2NuVasive Announces Conference Call and Webcast Regarding Reimbursement 3iThemba Pharmaceuticals (Pty) Ltd and Pyxis Discovery B.V. Announce Collaborative Agreement to Offer a Combined Service Offering 2DynaVox EyeMax Featured in Good Morning America Segment About Man Thought To Be in Coma for 23 Years 2FDA Approves NovoLog 28R 29 Labeling Update 51814 1FDA Approves NovoLog 28R 29 Labeling Update 51814 2FDA Approves NovoLog 28R 29 Labeling Update 51814 3FDA Approves NovoLog 28R 29 Labeling Update 51814 4U S Students Academic Interests Tend to Wane in Middle School 51812 1U S Students Academic Interests Tend to Wane in Middle School 51812 2Michael Steele Chairman of the Republican National Committee Will Hold a Press Conference on Health Care the Republican Alternative at 9 am on Mon 51810 1
...at data,presented recently at the 17th Annual Meet...iology demonstrate that the Genous Bio-engineered ...eluting stents., Presented by Federico Piscione, ...fessor with the Federico II University of Naples,s...dicine and Cardiovascular,Sciences, the data were ...
...ion Application currently u...erapeutics, Inc. (CTI),(Nasdaq: CTIC ; MTA) today...domized phase III trial comparing OPAXIO(TM) (pacl...orelbine for the treatment of PS 2,(performance st...ll cell,lung cancer (NSCLC) in the Journal of Thor...
Other Medicine Technology:Data Presented at Annual Meeting of Japanese Society of Interventional Cardiology Demonstrate OrbusNeich's Genous(TM) Bio-engineered R Stent(TM) Has Better Outcomes When Compared to Drug-Eluting Stents 2Data Presented at Annual Meeting of Japanese Society of Interventional Cardiology Demonstrate OrbusNeich's Genous(TM) Bio-engineered R Stent(TM) Has Better Outcomes When Compared to Drug-Eluting Stents 3Complete Study Results Comparing CTI's OPAXIO(TM) With Gemcitabine or Vinorelbine in Performance Status (PS 2) NSCLC Patients Published in Journal of Thoracic Oncology 2Complete Study Results Comparing CTI's OPAXIO(TM) With Gemcitabine or Vinorelbine in Performance Status (PS 2) NSCLC Patients Published in Journal of Thoracic Oncology 3Complete Study Results Comparing CTI's OPAXIO(TM) With Gemcitabine or Vinorelbine in Performance Status (PS 2) NSCLC Patients Published in Journal of Thoracic Oncology 4Complete Study Results Comparing CTI's OPAXIO(TM) With Gemcitabine or Vinorelbine in Performance Status (PS 2) NSCLC Patients Published in Journal of Thoracic Oncology 5
...ested Timeter® Classic Flowmeters demonstrates...oviders and patients alike. You can see it in the ... can see it in the performance, year after year. E...d and engineered to the highest standards of perfo...
Soft-Touch Timeter® 15 LPM Dual Oxygen Flowmeter w/Y Bar & 2 Power Take Off
Soft-Touch Timeter® 15 LPM Dual Oxygen Flowmeter w/T Bar
Soft-Touch Timeter® 8 LPM Flowmeter
Medicine Products: